Biogen (BIIB) vs BioMarin Pharmaceutical (BMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biogen (BIIB) has outperformed BioMarin Pharmaceutical (BMRN) over the past year, gaining 44.7% versus a gain of 0.4%. Over five years, BIIB leads with a -22.3% price change compared with -27.7% for BMRN. Biogen is the larger company by market cap ($32.27 billion vs $10.63 billion), about 3.0 times the size, while BioMarin Pharmaceutical is growing revenue faster (+12.9% vs +2.2%).
On valuation, BioMarin Pharmaceutical trades at a lower forward P/E (8.3x vs 13.2x for Biogen). Biogen converts more of its revenue into profit, with a net margin of 13.1% versus 10.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | BMRN |
|---|---|---|
| Share price | $218.43 | $54.89 |
| Market cap | $32.27B | $10.63B |
| 1-day change | -1.67% | -0.56% |
| YTD return | +24.12% | -7.64% |
| 1-year return | +44.68% | +0.37% |
| 5-year return | -22.32% | -27.67% |
| P/E ratio (TTM) | 38.80 | 148.35 |
| Forward P/E | 13.22 | 8.28 |
| EPS (TTM) | $5.63 | $0.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | $3.22B |
| Revenue growth (YoY) | +2.22% | +12.87% |
| Net income (latest FY) | $1.29B | $348.90M |
| Gross margin | 75.69% | 77.73% |
| Operating margin | — | 12.71% |
| Net margin | 13.07% | 10.83% |
| 52-week high | $230.49 | $70.98 |
| 52-week low | $138.00 | $49.26 |
| Distance from 52-week high | -5.23% | -22.67% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +9.04% | +66.92% |
| Average volume | 1.06M | 2.04M |
| Shares outstanding | 147.75M | 193.57M |
| Employees | 7,500 | 3,221 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biogen is about 3.0 times larger than BioMarin Pharmaceutical by market value ($32.27B vs $10.63B).
- BIIB has outperformed BMRN by 44.3 percentage points over the past year.
- BioMarin Pharmaceutical trades at a higher earnings multiple (148.4x vs 38.8x trailing P/E).
- BioMarin Pharmaceutical grew revenue faster in its latest fiscal year (+12.87% vs +2.22%).
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About BioMarin Pharmaceutical
BMRN stock →BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,221 employees
BIIB vs BMRN FAQ
Which is bigger, Biogen or BioMarin Pharmaceutical?
Biogen (BIIB) is larger, with a market capitalization of $32.27B compared with $10.63B for BioMarin Pharmaceutical (BMRN).
Which stock has performed better over the past year, BIIB or BMRN?
BIIB returned +44.68% over the past 12 months, compared with +0.37% for BMRN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, BIIB or BMRN?
BIIB has the lower trailing P/E at 38.8, versus 148.4 for BMRN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Biogen and BioMarin Pharmaceutical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Biogen and Biotechnology: Pharmaceutical Preparations for BioMarin Pharmaceutical.